The long term effects of GLP 1 medications are increasingly clear from multi-year trial extensions like STEP 5, the cardiovascular SELECT trial, and large registries: durable weight loss with continued therapy, meaningful cardiovascular benefit in higher-risk populations, and a generally manageable safety profile with several monitored signals. What is still emerging is what happens with five-plus years of continuous use.
What “Long Term” Means in GLP-1 Research
For most published trials, “long term” currently spans 1-3 years of continuous use. The longest randomized extension data come from STEP 5 (2 years on semaglutide), SUSTAIN 6 (2.1 years average), LEADER (3.8 years on liraglutide), and SELECT (mean 39.8 months on semaglutide). Registry and post-marketing surveillance fill some of the gap beyond trial windows but cannot substitute for randomized data. For broader context on metabolic care, see our prediabetes treatment overview.
Long Term Weight Outcomes
STEP 5 Two-Year Data
STEP 5 randomized 304 adults with obesity (without diabetes) to weekly semaglutide 2.4 mg or placebo for 104 weeks. Mean weight loss was 15.2% on semaglutide vs. 2.6% on placebo. Improvements in waist circumference, blood pressure, and lipid markers were also sustained.
Tirzepatide Long Term Data
SURMOUNT-4 evaluated whether continued tirzepatide maintained weight loss after a 36-week lead-in. Participants who continued tirzepatide maintained or extended weight loss; those switched to placebo regained substantial weight. Total study duration was 88 weeks.
What Happens After Stopping
The STEP 1 extension and SURMOUNT-4 both confirm a consistent pattern: most weight loss is regained in the year after discontinuation. Modern obesity medicine increasingly frames GLP-1 therapy as a chronic treatment, similar to antihypertensives.
Long Term Cardiovascular Outcomes
SELECT (Semaglutide)
SELECT randomized 17,604 adults with overweight or obesity and established cardiovascular disease (no diabetes) to weekly semaglutide 2.4 mg or placebo. Over a mean follow-up of 39.8 months, semaglutide reduced major adverse cardiovascular events (cardiovascular death, nonfatal MI, nonfatal stroke) by 20%. Results were published in the New England Journal of Medicine in 2023.
Other GLP-1 CV Outcomes
- LEADER (liraglutide, T2D): 13% relative reduction in MACE over 3.8 years
- SUSTAIN 6 (semaglutide, T2D): 26% relative reduction in MACE over 2.1 years
- REWIND (dulaglutide, T2D): 12% relative reduction in MACE over 5.4 years
Long Term Adverse Event Signals
Gastrointestinal
GI symptoms (nausea, vomiting, diarrhea, constipation) typically improve over the first months and remain low long term. Persistent nausea or vomiting beyond the titration phase warrants evaluation.
Pancreatitis and Gallbladder Disease
Both are listed FDA warnings. Long term and meta-analytic data show small but real increases in gallbladder events with weight loss generally and with GLP-1 therapy specifically. Pancreatitis signals remain under surveillance but have not consistently risen above background rates in large pharmacovigilance reviews.
Thyroid C-Cell Tumors
Boxed warnings reflect rodent data. Human registry surveillance to date has not confirmed an increased risk of medullary thyroid carcinoma in humans, but follow-up is ongoing.
Lean-Mass and Bone Loss
Rapid weight loss of any cause reduces lean mass. STEP and SURMOUNT subgroup analyses suggest roughly 25-40% of weight lost may be lean tissue without resistance training. Adequate protein intake (typically 1.0-1.6 g/kg) and resistance training are recommended to preserve muscle.
Other Areas Under Surveillance
- Gastroparesis – rare but reported, especially in patients with pre-existing motility issues
- Aspiration during anesthesia – prompted updated peri-procedural fasting guidance
- Psychiatric symptoms and suicidal ideation – large studies including a 2024 NIH analysis have not found increased risk relative to comparators
- Acute kidney injury – usually secondary to dehydration from severe vomiting or diarrhea
| Long-Term Outcome | Evidence | Direction |
|---|---|---|
| Sustained weight loss (2 yr) | STEP 5 | Maintained 15.2% |
| Cardiovascular events | SELECT, LEADER, SUSTAIN 6 | 20% reduction (SELECT) |
| A1C improvement | SUSTAIN, SURPASS programs | Sustained 1.5-2.3% drop |
| Gallbladder disease | Meta-analysis | Modest increase |
| Pancreatitis | Pharmacovigilance | Listed warning; absolute risk low |
| MTC in humans | Registry data | No confirmed signal |
What We Still Do Not Know
- What happens with 5-10+ years of continuous use
- Whether long-term cardiovascular benefit extends to lower-risk populations
- The long-term effect on bone density in older adults
- Whether observational signals (kidney protection, possible neurocognitive effects) hold up in randomized trials
- Outcomes of intermittent or cyclic use vs. continuous therapy
How to Use the Long-Term Data With Your Clinician
Useful framing for shared decision-making:
- What is your indication and baseline cardiovascular risk?
- How much benefit might you expect over 1-3 years?
- How will you mitigate lean-mass loss with protein and resistance training?
- What is the plan if you stop, including expected regain?
- How often will you screen for gallbladder, kidney, and metabolic markers?
Our A1C test guide can help you track glycemic outcomes alongside therapy.
The Bottom Line
The long term effects of GLP 1 medications, on the available evidence, are durable weight loss with continued therapy, meaningful cardiovascular benefit in higher-risk populations, and a generally acceptable safety profile with monitored signals for pancreatitis, gallbladder disease, and lean-mass loss. Five-plus year continuous-use data are still maturing. Decisions should be individualized with your clinician.
Medical disclaimer: This article is for educational purposes only and is not medical advice. Always consult your physician or a qualified healthcare provider before starting, stopping, or changing any medication or treatment plan.
